HIV Prevention & Treatment Research :: HIV / AIDs Treatment Studies

We offer a wide range of studies for people living with HIV. To find out more, see our "current studies" and select the type of study you are interested in.

Also call us to learn more about our HIV/AIDS Treatment studies
(212) 305-7897.

Bringing Together Care and Research for Better, Safer, and More Effective Treatments

HIV research studies are essential to provide critical information to help people live longer, healthier, and more comfortable lives.

Our mission has been to develop and provide the highest-quality treatment and care for people living with HIV through research.

We are part of the AIDS Clinical Trials Group (ACTG) of the National Institutes of Health (NIH). The ACTG, the largest HIV clinical-trials organization, plays a major role in defining the standards of care for treatment of HIV infection and opportunistic diseases related to HIV/AIDS around the world.

$Current Studies\$

Treatment Experienced
Hepatitis

Treatment Experienced

The following studies are for people who are treatment experienced, meaning that they are currently on medications or have taken medications in the past for HIV. Each study has a unique approach: Which are the best medications to treat with? When is the best time to change medications? How do we know when to change medications?

Study Number	A5212
Study Name	A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy
Description	This study will evaluate whether palifermin (recombinant human keratinocyte growth factor [rHuKGF]) can increase CD4+ lymphocyte counts by stimulating the thymus in HIV-1 infected adults with suppressed viral loads on potent antiretroviral therapy, but inadequate CD4+ recovery. Subjects will be randomized to one of four treatment arms to receive either placebo or one of three dose levels of palifermin intravenously (IV) daily for 3 days. Subjects will be followed on study for a total of 24 weeks. Arm A: palifermin placebo Arm B: palifermin 20 mcg/kg Arm C: palifermin 40 mcg/kg Arm D: palifermin 60 mcg/kg
Who Is Eligible	HIV-1 infected men and women ages 18 and older, on potent antiretroviral therapy with plasma HIV-1 RNA ≤200 copies/mm3 for at least 6 months and CD4+ lymphocyte counts ≤250cells/mm3
For More Information	Call (212) 305-7897 or e-mail

Study Number	A5240
Study Name	A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV–1 infected Females.
Description	This study will assess the immunogenicity, safety, and tolerability of the quadrivalent human papillomavirus (HPV) recombinant vaccine (GARDASIL) directed against types 6, 11, 16, 18. All participants will be vaccinated by intramuscular injection at day 0 and weeks 8 and 24, and followed for a total of 72 weeks.
Who Is Eligible	HIV infected females > 13 and < 45 years of age No restrictions on antiretroviral use or CD4 count No history of cervical cancer or CIN II or III, or previous cervical dysplasia treatment
For More Information	Call (212) 305-7897 or e-mail

Study Number	A5241
Study Name	The Optimized Treatment that Includes or Omits NRTIs (OPTIONS) Trial: A Randomized Strategy Study for HIV-1-infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen
Description	This is a strategy study for triple-class antiretroviral-experienced or resistant HIV-1 infected subjects that will evaluate the benefit of adding nucleoside reverse transcriptase inhibitors (NRTIs) to a new antiretroviral regimen. A continuous phenotype susceptibility score (cPSS) will be calculated based upon a real-time HIV-1 phenotype/genotype and co-receptor tropism assays to help in selecting a potent salvage regimen. Subjects for whom a study regimen with a cPSS>2.0 can be identified will be randomized to receive a new regimen with or without NRTIs. The study team will recommend options for a new regimen, which may include raltegravir, maraviroc, enfuvirtide, darunavir, tipranavir, or etravirine. The site investigator and subject will choose from the recommended options.
Who Is Eligible	HIV-1 infected individuals ages 16 and older HIV-1 RNA>1000 on a protease inhibitor-containing regimen Triple-class experience or resistance and no prior exposure to integrase inhibitor
For More Information	Call (212) 305-7897 or e-mail

Hepatitis

People with HIV may also be infected with other viruses, such as Hepatitis B or Hepatitis C. There are trials for the treatment of co-infected patients.

Study Number	A5232
Study Name	Optimizing Vaccine Responsiveness in HIV-1 and HCV Infections by Identifying Determinants of Responsiveness: A Pilot Study
Description	This is a study to evaluate the immune deficiencies in HIV-1 infected, HCV infected, and HIV/HCV co-infected individuals and determine whether these defects predict response to vaccinations: hepatitis A/hepatitis B immunization and diphtheria/tetatnus toxoid immunization
Who Is Eligible	Men and women age 18-65 who are hepatitis A antibody negative, hepatitis B surface antibody and antigen negative, and tetanus antibody negative HIV-1 infected with CD4≥300, no prior opportunistic infection, and not on antiretroviral therapy OR HCV infected without cirrhosis and no previous HCV treatment OR HIV-1 and HCV co-infected
For More Information	Call (212) 305-7897 or e-mail